WDR57 inhibitors are a class of chemical compounds specifically designed to target and inhibit the function of the WDR57 protein, a member of the WD repeat-containing protein family. WDR57, like other proteins in this family, contains highly conserved WD40 repeat domains that play an essential role in mediating protein-protein interactions. These WD40 domains are critical for the formation of multiprotein complexes, which are involved in regulating various cellular processes such as signal transduction, transcriptional control, and protein degradation. Although the precise function of WDR57 is still being investigated, it is believed to participate in processes related to cellular communication, gene regulation, and protein homeostasis. By inhibiting WDR57, these compounds disrupt its ability to assemble and stabilize molecular complexes, leading to alterations in the cellular pathways that rely on its regulatory roles.
The mechanism of WDR57 inhibitors typically involves binding to the WD40 repeat domains or other key regions of the protein, preventing it from interacting with other proteins in the cell. This inhibition interferes with WDR57's capacity to mediate crucial interactions in processes such as chromatin remodeling, cell cycle regulation, and protein trafficking. Researchers use WDR57 inhibitors to explore the specific functions of this protein within these molecular networks, seeking to understand its contributions to broader cellular systems. By blocking WDR57 activity, these inhibitors provide valuable insights into how WD repeat-containing proteins like WDR57 help orchestrate complex molecular interactions and ensure proper cellular function. Understanding the biological role of WDR57 through the use of these inhibitors can shed light on the fundamental mechanisms governing cellular structure, signaling, and protein turnover.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Could intercalate into DNA, disrupting RNA synthesis and potentially inhibiting WDR57 expression. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Could inhibit protein synthesis by blocking the translation process, potentially affecting WDR57 expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Might inhibit mTOR signaling, affecting protein synthesis and potentially the expression of WDR57. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $173.00 $418.00 | 43 | |
May intercalate DNA and disrupt transcription, potentially inhibiting the expression of WDR57. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
Might incorporate into RNA, disrupting RNA processing and potentially affecting WDR57 expression. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $65.00 $99.00 $140.00 | 85 | |
Could crosslink DNA, disrupting transcription and potentially affecting WDR57 expression. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
Might inhibit DNA topoisomerase I, affecting DNA replication and possibly WDR57 expression. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
Could inhibit dihydrofolate reductase, affecting DNA synthesis and potentially WDR57 expression. | ||||||
2′-Deoxy-2′,2′-difluorocytidine | 95058-81-4 | sc-275523 sc-275523A | 1 g 5 g | $56.00 $128.00 | ||
Might inhibit DNA synthesis, potentially affecting the replication process and WDR57 expression. | ||||||